How This MSK Center Takes Care of Younger Patients With Colorectal and Gastrointestinal Cancers

Andrea Cercek, MD
Gastrointestinal Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Section Head, Colorectal Cancer
- Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
I am a board-certified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer (CRC), appendix cancer, and cholangiocarcinoma. My research is focused on the development of novel systemic and regional therapies, including approaches based on tumor genomics, with the goal of improving outcomes while minimizing treatment-related toxicities.
I am the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic — the first of its kind in the world — is dedicated solely to the specific needs of people under 50 who have CRC or other GI cancers.
A gastrointestinal (GAS-troh-EN-teh-RAH-loh-jist) oncologist is a cancer doctor with special training in the gastrointestinal (GI) system. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Colon Cancer
- Rectal Cancer
- Anal Cancer
- Appendiceal Cancer
- Young Onset Colorectal Cancer
- Cholangiocarcinoma
Education
- MD, New York Medical College
Residencies
- Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
Awards and Honors
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

New Patients
Current Patients
Contact and Location
Dr. Cercek sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Cercek
- A Phase 2 Study of Dostarlimab in People With Previously Untreated Rectal Cancer
- A Phase II Study of Dostarlimab Immunotherapy in People with Locally Advanced "Mismatch Repair-Deficient" Rectal Cancer
- A Phase II Study of Gemcitabine and Oxaliplatin Chemotherapy with or without a Floxuridine and Dexamethasone Pump in People with Inoperable Cholangiocarcinoma
- A Phase II Study of Tucatinib and Trastuzumab Followed by Chemotherapy as Initial Treatment for Locally Advanced HER2-Positive Rectal Cancer
Read more
- A Phase III Study of Tucatinib with Trastuzumab and mFOLFOX6 Chemotherapy versus Standard Care as Initial Treatment for HER2+ Metastatic Colorectal Cancer
- A Study Assessing the Effects of Chemotherapy or Radiation Therapy on Reproductive and Sexual Health in People with Early-Onset Colorectal Cancer
- Clinical Trials Co-Investigated by Dr. Cercek
- A Phase 2/3 Study of BRAF-Targeted Therapy After Surgery and Chemotherapy for BRAF-Mutated Colon Cancer
- A Phase I Study of PF-07062119 Immunotherapy in People with Advanced Digestive Cancers
- A Phase II Study Assessing the Addition of Irinotecan to Combination Chemotherapy after Chemoradiation in Patients with Stage II or III Rectal Cancer to Improve the Rate of Complete Response
- A Phase III Study of MRTX849 Combined with Cetuximab versus Chemotherapy in People with KRAS G12C-Mutated Advanced Colorectal Cancer that Continues to Grow
- A Phase III Study of Nivolumab plus Chemotherapy for Patients with Advanced Anal Cancer
- ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Phase II Study of Early Post-Operative Abdominal Chemotherapy versus Heated Abdominal Chemotherapy for Cancers of the Appendix, Colon, or Rectum that Have Spread to the Abdominal Lining

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Cercek’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrea Cercek discloses the following relationships and financial interests:
-
Bayer
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities -
Haystack Oncology, Inc.
Equity -
Janssen Oncology, Inc.
Professional Services and Activities
-
Merck & Co Inc.
Professional Services and Activities -
Roche Diagnostics Asia Pacific Pte Ltd
Professional Services and Activities -
Seagen
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].